Immunotherapeutic strategies in autoimmune uveitis
- PMID: 24833504
- PMCID: PMC4181827
- DOI: 10.1016/j.autrev.2014.05.003
Immunotherapeutic strategies in autoimmune uveitis
Abstract
Autoimmune uveitis is an organ-specific disorder characterized by irreversible lesions to the eye that predominantly affect people in their most productive years and is among the leading causes of visual deficit and blindness. Currently available therapies are effective in the treatment of a wide spectrum of uveitis, but are often associated with severe side effects. Here, we review ongoing research with promising immunomodulatory therapeutic strategies, describing their specific features, interactions and the responses triggered by the targeted immune molecules that aim to minimize clinical complications and the likelihood of disease relapse. We first review the main features of the disease, diagnostic tools, and traditional forms of therapy, as well as the animal models predominantly used to understand the pathogenesis and test the novel intervention approaches aiming to control the acute immune and inflammatory responses and to dampen chronic responses. Both exploratory research and clinical trials have targeted either the blockade of effector pathways or of their companion co-stimulatory molecules. Examples of targets are T cell receptors (CD3), their co-stimulatory receptors (CD28, CTLA-4) and corresponding ligands (B7-1 and B7-2, also known as CD80 and CD86), and cytokines like IL-2 and their receptors. Here, we summarize the available evidence on effectiveness of these treatments in human and experimental uveitis and highlight a novel CD28 antagonist monovalent Fab' antibody, FR104, which has shown preclinical efficacy suppressing effector T cells while enhancing regulatory T cell function and immune tolerance in a humanized graft-versus-host disease (GVHD) mice model and is currently being tested in a mouse autoimmune uveitis model with encouraging results.
Keywords: Autoimmune uveitis; CD28 antagonists; Costimulation blockade; Experimental autoimmune uveitis; Immune modulation.
Copyright © 2014. Published by Elsevier B.V.
Figures

Similar articles
-
Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.PLoS One. 2017 Mar 1;12(3):e0171822. doi: 10.1371/journal.pone.0171822. eCollection 2017. PLoS One. 2017. PMID: 28248972 Free PMC article.
-
Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance.J Immunol. 2000 Nov 1;165(9):5041-7. doi: 10.4049/jimmunol.165.9.5041. J Immunol. 2000. PMID: 11046033
-
Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody.Am J Transplant. 2012 Oct;12(10):2630-40. doi: 10.1111/j.1600-6143.2012.04164.x. Epub 2012 Jul 3. Am J Transplant. 2012. PMID: 22759318
-
Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade.J Pept Res. 2005 Jun;65(6):591-604. doi: 10.1111/j.1399-3011.2005.00256.x. J Pept Res. 2005. PMID: 15885118 Review.
-
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.Annu Rev Immunol. 2001;19:225-52. doi: 10.1146/annurev.immunol.19.1.225. Annu Rev Immunol. 2001. PMID: 11244036 Review.
Cited by
-
Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA/circRNA immune ceRNA networks.BMC Complement Altern Med. 2019 Jul 3;19(1):156. doi: 10.1186/s12906-019-2577-6. BMC Complement Altern Med. 2019. PMID: 31269941 Free PMC article.
-
LncRNA Neat1 targets NonO and miR-128-3p to promote antigen-specific Th17 cell responses and autoimmune inflammation.Cell Death Dis. 2023 Sep 16;14(9):610. doi: 10.1038/s41419-023-06132-0. Cell Death Dis. 2023. PMID: 37716986 Free PMC article.
-
Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.JCI Insight. 2017 Feb 9;2(3):e90088. doi: 10.1172/jci.insight.90088. JCI Insight. 2017. PMID: 28194440 Free PMC article.
-
Neopterin Levels and Immune Response in Autoimmune Uveitis in an Experiment.Korean J Ophthalmol. 2025 Jun;39(3):258-268. doi: 10.3341/kjo.2024.0118. Epub 2025 May 28. Korean J Ophthalmol. 2025. PMID: 40436069 Free PMC article.
-
The DNA Methylation Inhibitor Zebularine Controls CD4+ T Cell Mediated Intraocular Inflammation.Front Immunol. 2019 Aug 16;10:1950. doi: 10.3389/fimmu.2019.01950. eCollection 2019. Front Immunol. 2019. PMID: 31475011 Free PMC article.
References
-
- Gritz D.C., Wong I.G. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500. [discussion 500] - PubMed
-
- Whitcup S.M., Nussenblatt R.B. Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol. 1997;115(4):520–525. - PubMed
-
- Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014;13(4–5):591–594. - PubMed
-
- Comarmond C.B., Wechsler B., Bodaghi B., Cacoub P., Saadoun D. Biotherapies in Behcet's disease. Autoimmun Rev. 2014;13(7):762–769. - PubMed
-
- Selmi C., Gershwin M.E. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4–5):546–549. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical